What the FDA labels say about taking them together
Lenvatinib and sorafenib
Lenvatinib's FDA label of June 30, 2026 names sorafenib in its warnings and precautions section; the sorafenib label PlainMeds reads does not name lenvatinib.
Check it at the source: the lenvatinib FDA label on DailyMed (effective June 30, 2026, Eisai Inc.); the sorafenib FDA label on DailyMed (effective August 28, 2023, Bayer HealthCare Pharmaceuticals Inc.).
What does the lenvatinib label say about sorafenib?
Lenvatinib label, warnings and precautionsTwo percent of patients discontinued LENVIMA and 0.2% discontinued sorafenib due to hepatic encephalopathy and 1% of patients discontinued LENVIMA or sorafenib due to hepatic failure [see Adverse Reactions ( 6.1 )].
Source: FDA drug label (Lenvima), Eisai Inc., effective June 30, 2026 (SPL set f4bedd21-efde-44c6-9d9c-b48b78d7ed1e), via openFDA; the full label on DailyMed
What does the sorafenib label say about lenvatinib?
Sorafenib's label (effective August 28, 2023) does not name lenvatinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nexavar), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2023 (SPL set b50667e4-5ebc-4968-a646-d605058dbef0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lenvatinib | Sorafenib | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once